Richard B. Brewer
Richard B. Brewer | |
|---|---|
| Born | April 6, 1951 Virginia Tech Northwestern University |
| Scientific career | |
| Institutions | Genentech Heartport Scios Myrexis |
Richard Brooke Brewer (April 6, 1951 – August 15, 2012) was a
Education
Brewer received a bachelor of science from
Career
From 1984 to 1995, Brewer was the senior vice president of sales and marketing and later the senior vice president of Genentech Europe and Canada.[4] Brewer was then the chief operating officer of Heartport from 1996 to 1998.
In 1998, he became the president and chief executive officer of Scios, a position he held until 2004. In 2001, he was diagnosed with multiple myeloma, a form of blood cancer.[2] He was the managing partner of Crest Asset Management from 2003 to 2009.[4]
In his career, Brewer guided development and commercialization of breakthrough drugs including human growth hormone for children's growth disorders; the first new drug in 30 years for cystic fibrosis; the first new drug in over a decade for heart failure; clot-busting drugs for heart attacks and strokes; and other drugs and devices for cancer and heart disease.[3]
He served on the board of directors of several companies, including SRI International. At the time of his death, he was chairman of the board of ARCA biopharma and Dendreon Corporation, and was executive chairman of Nile Therapeutics.[4]
References
- ^ "Richard B. Brewer". Forbes. Archived from the original on May 3, 2009. Retrieved 2012-01-17.
- ^ a b c d "Richard Brewer". San Francisco Chronicle. 2012-08-20. Retrieved 2012-08-25.
- ^ a b "Myrexis Announces Death of Chief Executive Officer Richard B. Brewer, Trailblazing Biotechnology Industry Veteran and Patient Advocate". Myrexis. Archived from the original on November 5, 2012. Retrieved 2012-08-15.
- ^ a b c d "Biotechnology Industry Veteran Richard Brewer Joins SRI International Board of Directors". SRI International. 2006-01-09. Retrieved 2012-08-25.